Results 71 to 80 of about 57,995 (263)

Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family [PDF]

, 2020
Head and neck paragangliomas are the most common clinical features of familial paraganglioma syndrome type 1 caused by succinate dehydrogenase complex subunit D (SDHD) mutation. The clinical management of this syndrome is still unclear.
Cantisani, Vito, Colao, Annamaria, Di Leo, Nicola, Faggiano, Antongiulio, Feola, Tiziana, Giannetta, Elisa, Isidori, Andrea M, Lenzi, Andrea, Modica, Roberta, Polti, Giorgia, Puliani, Giulia, Sesti, Franz, Verrico, Monica   +12 more
core   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive

Drug Delivery, 2021
The purpose of this study was to optimize the preparation method of injectable Octreotide microspheres. To explore the correlation between the solvent system and the general properties of microspheres to reduce burst release and enable them to be used ...
Bing Han, Huan Tang, Qiming Liang, Ming Zhu, Yizhuo Xie, Jinglin Chen, Qianwen Li, Juan Jia, Yan Li, Zhihui Ren, Dengli Cong, Xiaofeng Yu, Dayun Sui, Jin Pei   +13 more
doaj   +1 more source

Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats

Angiogenesis, 2016
Abnormal angiogenesis is critical for portal hypertension in cirrhosis. Except for etiological treatment, no efficient medication or regime has been explored to treat the early stage of cirrhosis when angiogenesis is initiated or overwhelming.
Jinhang Gao, Shilei Wen, Shi Feng, Wen-juan Yang, Yaoyao Lu, H. Tong, Rui Liu, Shi Tang, Zhi-yin Huang, Ying-mei Tang, Jin-hui Yang, Huiqi Xie, Cheng-Wei Tang   +12 more
semanticscholar   +1 more source

The use of octreotide in the treatment of chylothorax

Journal of Contemporary Medicine, 2019
Chylothorax is defined as abnormal accumulation of lymphatic fluid in the pleural space. Chylothorax is a rare case and generally occurs after thoracic and cardiac procedures.
Hıdır Esme
doaj   +1 more source

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +2 more sources

Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications

Medicinal Research Reviews, EarlyView.
ABSTRACT Targeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 (211At) has experienced increased interest due to its favorable decay properties.
Marius Müller, Nadia Bom Pedersen, Vladimir Shalgunov, Andreas Ingemann Jensen, Umberto Maria Battisti, Matthias Manfred Herth   +5 more
wiley   +1 more source

Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis

BMC Pharmacology and Toxicology, 2017
Background Many patients with acromegaly require medical treatment that includes somatostatin analogs (SSAs). Long-acting SSA formulations are widely used, due in part to increased patient convenience and increased treatment adherence vs daily ...
Michelle H. Gurel, Yi Han, Andrea L. Stevens, Aaron Furtado, David Cox   +4 more
doaj   +1 more source

A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation. [PDF]

PLoS ONE, 2012
The newly developed multireceptor somatostatin analogs pasireotide (SOM230), octreotide and somatoprim (DG3173) have primarily been characterized according to their binding profiles.
Andrea Kliewer, Anika Mann, Aline Petrich, Florian Pöll, Stefan Schulz   +4 more
doaj   +1 more source

Effects of somatostatin/octreotide treatment in neonates with congenital chylothorax

Medicine, 2017
The influence of somatostatin/octreotide treatment on outcomes of neonates with congenital chylothorax remains controversial. We retrospectively reviewed our experience with somatostatin/octreotide therapy in neonates with this very rare disease ...
Rong Yin, Rong Zhang, Jin Wang, Lin Yuan, Liyuan Hu, Siyuan Jiang, Chao Chen, Yun Cao   +7 more
semanticscholar   +1 more source